Answer The new pharmacy pill for weight loss is promising as a post-glp-1 maintenance treatment

Poor tolerability of GLP-1 obesity drugs leads many patients to stop taking them, which made it possible to resume the weight that was lost. Certain pharmaceutical companies are trying to develop other approaches that could serve as maintenance therapies after initial treatment with GLP-1 injections, and responding pharmaceuticals has now encouraged the creation of mid-term clinical data of the case for its pill.

The response medication, RDX-002, is a small oral molecule designed to inhibit a target called Triglyceride Transfer Protein Intestinal Microsomal (IMTP). Biotech based at the church of Falls, based in Virginia, says that this approach reduces the absorption of triglycerides (fat) and cholesterol by the body. Therefore, the body takes fewer calories.

The answer assessed the RDX-002, taken as a pill twice a day, in a phase 2 test which scored 68 participants who had stopped or were ready to interrupt the Novo Nordisk GLP-1 Drug Wegovy or the Zepbound Elilly GLP-1 and GIP Receptor Agonist. The main objective was to measure the change in triglyceride levels, compared to placebo, after 12 weeks. The secondary objectives include measurement of the change in body weight and cholesterol levels.

According to the results published on Wednesday, the response medication left statistically significant reductions in blood fat levels after eating. In addition, the 12 -week results have shown that these discounts were also associated with a reduction in weight deduction from a placebo. The startup said that the RDX-002 was generally well tolerated, characterizing adverse events as mainly light to moderate gastrointestinal effects. No serious adverse event has been reported. The company said that the complete data in phase 2 will be presented at a next scientific meeting.

RDX-002 was discovered and initially developed by surface Logix, a biotechnology acquired by Kadmon Pharmaceuticals. In 2021, Sanofi paid $ 1.9 billion to acquire Kadmon, an agreement focused mainly on Rezurock, a rock2 inhibitor which reached the market as the treatment of chronic transplant disease against the host. Response authorized global rights to SANOFI RDX-002. According to Response’s website, the co-founder of the company and scientific director Paul Sweetnam led the discovery of RDX-002 to Surface Logix. The answer announced funding of $ 8 million in 2022.

The main indication of RDX-002 is to treat the weight gain of antipsychotics, a common side effect of these drugs. A separate phase 2 program is underway in this indication. But helping patients maintain weight loss after treatment for GLP-1 opens up another opportunity for biotechnology.

“By targeting the key routes involved in metabolic regulations, we aim to provide a lasting and well tolerated solution that supports long -term weight management and cardiometabolic health,” said the CEO of response, Eric Keller, in a prepared press release. “We remain determined to advance the development of RDX -002 in our main indication – weight gain induced by antipsychotics (AIWG) – targeting a metabolically highly vulnerable population, as well as to explore their potential in other areas with a significant metabolic need.”

Photo: Peter Dazeley, Getty Images